Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

M-2 protocol for melphalan-resistant and relapsing multiple myeloma.

M Cavo1, P Galieni, C Tassi

  • 1Institute of Haematology Lorenzo e Ariosto Seràgnoli, University of Bologna, Italy.

European Journal of Haematology
|February 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.

European journal of haematology·2026
Same author

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide.

Clinical and experimental medicine·2025
Same author

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Journal of cancer research and clinical oncology·2025
Same author

Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.

Journal of bone oncology·2025
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.

Cancer medicine·2024

The M-2 protocol showed a 47% response rate in advanced multiple myeloma patients, particularly effective for those relapsing after alkylating agent chemotherapy. Further research is needed for primary non-responders.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Pharmacology

Background:

  • Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
  • Refractory and relapsed multiple myeloma pose significant treatment challenges.
  • Previous chemotherapy regimens, including alkylating agents, often lead to resistance or relapse.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of the M-2 protocol (vincristine, cyclophosphamide, carmustine, melphalan, and steroids) as a salvage treatment for advanced refractory multiple myeloma.
  • To assess treatment outcomes in patients with different prior responses to alkylating agents.

Main Methods:

  • A cohort of 33 patients with advanced refractory multiple myeloma was treated with the M-2 protocol.
  • Patients were stratified into two groups: those who failed prior chemotherapy with alkylating agents (non-responders) and those who relapsed after a response (relapsers).

Related Experiment Videos

  • Tumor cell mass reduction and toxicity were monitored.

    • Main Results:

    • An overall response rate of 47% was observed (39% in non-responders, 58% in relapsers).
    • Objective tumor cell mass reduction (≥50%) was achieved in 17% of patients.
    • Thrombocytopenia was the most frequent toxicity (39%).

    Conclusions:

    • The M-2 protocol demonstrates efficacy as a salvage therapy for multiple myeloma patients relapsing after alkylating agent chemotherapy.
    • For patients primarily resistant to alkylating agents, alternative treatment strategies are warranted to achieve greater tumor reduction.